| This week's sponsor is Premier Research. | | | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown | Publisher’s Note: In preparation for the new GDPR taking effect this month, we would like to reconfirm your subscription to our newsletter(s). Please click this link to reconfirm your subscription. For more information about GDPR, please visit this page. | |
|
Loxo RET inhibitor shines in early-phase trial Jounce plunges after ASCO abstract reveal Nektar slips on reduced response rates for Opdivo combo [Sponsored] Accelerating Timelines for Rare Disease Drug Development Syndax claims biomarker predicts increased benefit of HDAC/PD-1 combination in NSCLC Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies HiFiBiO raises $37.5M in series B following 2017’s management shuffle A 2-pronged attack could improve targeted therapies for colon cancer Featured Story | | | Thursday, May 17, 2018 Loxo Oncology has reported encouraging data from a phase 1 trial of RET inhibitor LOXO-292 in solid tumor patients. The drug shrunk the tumors of most patients in the trial, raising hopes it can become a new treatment option for patients with RET-altered cancers. |
|
|
Top Stories Thursday, May 17, 2018 Shares in Jounce Therapeutics plummeted upon the publication of an abstract for a phase 1/2 trial of its first-in-class ICOS inhibitor JTX-2011, although the company says the drug showed evidence of efficacy. Thursday, May 17, 2018 The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers, but Jefferies analysts called the data "stale" and said a more complete picture will be painted at ASCO. Monday, May 14, 2018 For children diagnosed with rare diseases, traditional drug development timelines are not good enough. Collaborative partnerships are imperative to accelerate those timelines and expedite time to market for rare disease therapies. Thursday, May 17, 2018 Syndax Pharmaceuticals’ combination of its HDAC inhibitor entinostat with Merck’s anti-PD-1 therapy Keytruda may have posted small gains in an ongoing phase 1b/2 study in non-small cell lung cancer, but the company believes it has identified an enrichment biomarker that could predict increased clinical benefit overall. Thursday, May 17, 2018 Novo Nordisk has talked up the progress of its Type 1 diabetes stem cell therapy program. With the diabetes project clearing milestones and moving within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly. Wednesday, May 16, 2018 HiFiBiO Therapeutics has completed a $37.5 million series B funding round, with plans to advance its antibody pipeline in oncology and autoimmune research after expanding its leadership team last summer. Wednesday, May 16, 2018 Two pathways have long been of interest to researchers studying colon cancer: Notch and MAPK. But drugs designed to target either pathway have proven disappointing. Now a team of researchers in Germany has made a discovery that sheds light on those disappointments—and provides insight that could improve colon cancer treatment. | This week's sponsor is Eurofins Advinus. | | | |
Resources Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: USDM Life Sciences What are the biggest trends in life sciences this year? Presented by: Patheon There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. In this article, the author discusses the choices available and strategies which can be employed at the different stages of development. Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: Veeva Systems To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights. Sponsored by: Veeva Systems Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Building your Program for Immunomodulating Therapeutics Wednesday, 6 June, 2018 | Paris, France Drug Development Immersion May 17-18, 2018 | Boston, MA BIO International Convention June 4-7, 2018 | Boston, MA
FierceBiotech Executive Breakfast at BIO 2018 – CAR-T 2.0: Innovation Never Stands Still June 6, 2018 | Boston, MA BioBasics: Biotech for the Non-Scientist June 13-14, 2018 | Toronto, Canada BioBasics: Biotech for the Non-Scientist June 13-14, 2018 | West Windsor, NJ Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 